RPG Life Sciences recommends ₹24 dividend; appoints Dr. Pratit Samdani as Director
RPG Life Sciences approved audited financial results for the quarter and year ended March 31, 2026. The Board recommended a dividend of ₹24 per share for FY 2025-26. Dr. Pratit Samdani was appointed as an Additional Non-Executive Independent Director for five years.
The dividend recommendation and appointment of a director are material events for shareholders and the company's governance structure.
The announcement is positive due to the recommendation of a significant dividend and the appointment of an independent director, indicating good corporate governance and financial health.
RPG Life Sciences Limited announced the outcome of its Board Meeting held on April 29, 2026. The Board approved the Audited Financial Results for the quarter and year ended March 31, 2026, both standalone and consolidated, along with the Statutory Auditor's Reports which received an unmodified opinion.
The Board recommended a dividend of ₹24 per equity share (300%) for FY 2025-26, subject to shareholder approval at the upcoming Annual General Meeting. This dividend will be paid or dispatched within 30 days of such approval.
Furthermore, Dr. Pratit Samdani (DIN: 10139232) was appointed as an Additional Non-Executive Independent Director for a term of five years, from April 29, 2026, to April 28, 2031. This appointment is subject to shareholder approval and is not liable to retire by rotation. Dr. Samdani is a highly respected physician with over two decades of experience in Internal Medicine and Critical Care, known for his clinical expertise and research contributions.
The Board also approved amendments to the Code of fair disclosure, internal procedures, and conduct for regulating, monitoring, and reporting of trading by designated persons and their immediate relatives. The updated code is available on the company's website. The trading window for dealing in the company's securities will open 48 hours after the declaration of the financial results.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.